MedTrace Logo

Metabolomic Biomarkers Evaluation in Pulmonary Fibrosis

NCT06974799 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 59

Last updated 2025-05-16

No results posted yet for this study

Summary

Pulmonary fibrosis (PF) are a heterogeneous group of interstitial lung diseases who may have a progressive phenotype often associated with loss of lung function, chronic respiratory symptoms, quality of life limitation as well significant morbidity and mortality. The identification of reliable biomarkers able to help in early diagnosis and predict disease progression are crucial for improving patient life. Although many biomarkers have been proposed, there is no consensus on reliable markers for IPF. Alterations in fatty acid (FA) metabolism have drawn increasing attention in the IPF pathogenesis, but there is no consensus on the specific FA changes. Alterations in FA composition have been shown to promote pro-fibrotic traits in epithelial cells, fibroblasts, and myofibroblasts. However, while specific fatty acid (FA) alterations have been identified in the serum of IPF patients, no consensus exists on the exact changes for individual FAs

Conditions

Interventions

DIAGNOSTIC_TEST

Fatty acids measurement

Serum analysis for metabolomic biomarker identification

Sponsors & Collaborators

  • Ceinge - Biotecnologie Avanzate s.c. a r.l.

    collaborator UNKNOWN

  • University of Campania Luigi Vanvitelli

    lead OTHER

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-05-05
Primary Completion
2024-07-15
Completion
2025-01-18

Countries

  • Italy

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06974799 on ClinicalTrials.gov